Exploring the association between antidepressants, progression and mortality in Huntington’s disease

Mclauchlan, Duncan, Drew, Cheney ORCID: https://orcid.org/0000-0002-4397-6252, Holmans, Peter ORCID: https://orcid.org/0000-0003-0870-9412 and Rosser, Anne ORCID: https://orcid.org/0000-0002-4716-4753 2026. Exploring the association between antidepressants, progression and mortality in Huntington’s disease. Brain 149 (8) , awag009. 10.1093/brain/awag009

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (627kB) | Preview

Abstract

Psychiatric symptoms are very common in Huntington’s disease (HD). In keeping with other neurodegenerative diseases, there are concerns that antidepressants may worsen disease progression. Previous work on antidepressant effects in HD has been limited by confounding by indication, small sample sizes, short follow-up or a combination of these. We leveraged data from the ENROLL-HD (25550 participants) cohort to determine if 1) symptoms associated with antidepressant initiation are associated with faster disease progression and 2) antidepressants have an impact on disease progression and mortality in people with HD (pwHD) experiencing these symptoms.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR)
Publisher:	Oxford University Press
ISSN:	0006-8950
Date of First Compliant Deposit:	28 January 2026
Date of Acceptance:	4 December 2025
Last Modified:	02 Sep 2026 11:06
URI:	https://orca.cardiff.ac.uk/id/eprint/184265

Actions (repository staff only)

Edit Item